Now, new research suggests that breast cancer patients with high levels of the vitamin in their blood are more likely to survive the disease than patients with low levels. The researchers, led by Prof. Cedric F. Garland of the University of California, San Diego School of Medicine, recently published their findings in the journal Anticancer Research.
Vitamin D - a fat-soluble vitamin - is important for regulating the absorption of calcium and phosphorus in our bones. The body's main source of the vitamin is from the sun, but some foods - such as oily fish, eggs and fortified fat spreads - contain the vitamin in very small amounts. Supplements are also available to boost vitamin D intake.
Prof. Garland notes that his past studies revealed an association between low vitamin D levels and an increased risk of premenopausal breast cancer. From this, he decided to look at the link between 25-hydroxyvitamin D - a metabolite that the body produces from vitamin D ingestion - and survival rates of breast cancer. Researchers have found that breast cancer patients with high vitamin D levels in their blood have a 50% lower fatality rate, compared with those who have low levels of the vitamin. The research team conducted a statistical analysis of five studies that looked at the link between 25-hydroxyvitamin D and breast cancer.
The studies included a total of 4,443 patients with breast cancer and were performed between 1966 and 2010. All patients were followed for an average of 9 years.
Patients were divided into groups dependent on the levels of 25-hydroxyvitamin D in their blood. Women in the "high" group had an average of 30 nanograms per milliliter (ng/ml) of 25-hydroxyvitamin D in their blood, while women in the "low" group had an average of 17 ng/ml in their blood.
The investigators note that the average blood level of 25-hydroxyvitamin D for breast cancer patients in the US is 17 ng/ml. High levels of vitamin D 'may halve breast cancer fatality'The team found that women who had high levels of 25-hydroxyvitamin D in their blood had around a 50% lower fatality rate, compared with women who had low levels of 25-hydroxyvitamin D in their blood.
Explaining why he believes vitamin D decreases fatality rates for breast cancer patients, Prof. Garland says that vitamin D metabolites increase communication between cells by activating a protein that halts aggressive cell division. "As long as vitamin D receptors are present, tumor growth is prevented and kept from expanding its blood supply," he adds. "Vitamin D receptors are not lost until a tumor is very advanced. This is the reason for better survival in patients whose vitamin D blood levels are high." But the researchers point out that these findings could be a result of reverse causation. They explain that in more serious breast cancer cases, it is possible that 25-hydroxyvitamin D levels were reduced, therefore causing early death.
"If that were so, 25-hydroxyvitamin D could be a biomarker for severity of cancer, rather than a factor that caused longer survival," they add. They say this possibility could be ruled out with further clinical trials.
Although Prof. Garland says further research is needed to confirms the team's findings, he believes there is no reason why people should not increase their vitamin D intake now, after confirming with their health care provider that it is safe to do so.
He refers to a study he conducted in 2011, which found that a 50 ng/ml level of 25-hydroxyvitamin D in the blood - a level that can be reached with an intake of 4,000 international units (IU) of vitamin D a day - reduces breast cancer risk by 50%.
The investigators say that based on their findings, patients with the disease may benefit from having 25-hydroxyvitamin D blood concentrations measured and adjusted to within normal range (30-80 ng/ml).
About Myriad myRisk™
Myriad myRisk is the only hereditary cancer test that combines your genetic information with the personal and family history you give your healthcare provider to generate guideline-based management options to help you lower cancer risks. The test result provides critical information for your healthcare provider to make optimal medical decisions and take action in building a personalized cancer risk-reduction plan. Myriad myRisk looks at multiple genes that impact inherited risks for eight important cancers. Testing multiple genes helps avoid missing mutations. Myriad myRisk incorporates your family history and genetic results to help optimizeyour medical management. Myriad myRisk is the gold standard in accuracy and offers fast turnaround time for panel testing.Myriad myRisk analyzes 25 genes associated with cancers such as breast, ovarian, endomeetrial, prostate, melanoma, pancreatic, colorectal and grastric.
Testing is now available to appropriate patients at LIBC. Call the x110 or x111 to see if you qualify for this testing.